Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Prepaid Assets (2022 - 2025)

Historic Prepaid Assets for Indivior Pharmaceuticals (INDV) over the last 3 years, with Q3 2025 value amounting to $30.0 million.

  • Indivior Pharmaceuticals' Prepaid Assets changed N/A to $30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.0 million, marking a year-over-year change of. This contributed to the annual value of $31.0 million for FY2024, which is 4038.46% down from last year.
  • Per Indivior Pharmaceuticals' latest filing, its Prepaid Assets stood at $30.0 million for Q3 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Prepaid Assets ranged from a high of $56.0 million in Q1 2025 and a low of $28.0 million during Q2 2025
  • For the 3-year period, Indivior Pharmaceuticals' Prepaid Assets averaged around $39.4 million, with its median value being $31.0 million (2024).
  • The largest annual percentage gain for Indivior Pharmaceuticals' Prepaid Assets in the last 5 years was 4038.46% (2024), contrasted with its biggest fall of 4038.46% (2024).
  • Indivior Pharmaceuticals' Prepaid Assets (Quarter) stood at $52.0 million in 2023, then plummeted by 40.38% to $31.0 million in 2024, then decreased by 3.23% to $30.0 million in 2025.
  • Its Prepaid Assets was $30.0 million in Q3 2025, compared to $28.0 million in Q2 2025 and $56.0 million in Q1 2025.